Obagi Medical Products, Inc. 

(Public, NASDAQ:OMPI)   Watch this stock   
Find more results for OMPI
Nov 5, 2009
Q3 2009 OBAGI MEDICAL PRODUCTS INC Earnings Conference Call - Webcast
Nov 5, 2009
Q3 2009 OBAGI MEDICAL PRODUCTS INC Earnings Release
Sep 21, 2009
OBAGI MEDICAL PRODUCTS INC at UBS Global Life Sciences Conference
Sep 10, 2009
OBAGI MEDICAL PRODUCTS INC at Robert W. Baird & Co., Inc. Health Care Conference
Sep 9, 2009
OBAGI MEDICAL PRODUCTS INC at Thomas Weisel Partners Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin 10.97% 12.04%
Operating margin 17.67% 19.12%
EBITD margin - 21.33%
Return on average assets 15.07% 19.07%
Return on average equity 18.18% 22.84%
Employees 218 -

Address

310 Golden Shore
Long Beach, CA 90802
United States - Map
+1-562-6281007 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Obagi Medical Products, Inc. discussed on blogs

Ranking Healthcare Stocks YTD 2009 - namshik - STOCKBOX.tv - asset bubble double dip recession stocks videos - 15 hours ago

Obagi Medical Products, Inc. discussions

  View all discussions »

Description

Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Officers and directors

Albert J. Fitzgibbons III
Chairman of the Board
Age: 63
Bio & Compensation - Reuters
Steven R. Carlson
President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
Preston S. Romm
Chief Financial Officer, EVP - Finance, Operations and Administration, Treasurer
Bio & Compensation - Reuters
David Goldstein
Executive Vice President - Global Sales and Field Marketing
Bio & Compensation - Reuters
Laura B. Hunter
Vice President, General Counsel, Secretary
Bio & Compensation - Reuters
John A. Bartholdson
Director
Age: 38
Bio & Compensation - Reuters
Edward A. Grant
Director
Age: 59
Bio & Compensation - Reuters
Albert F. Hummel
Director
Age: 64
Bio & Compensation - Reuters
Ronald P. Badie
Director
Age: 66
Bio & Compensation - Reuters
John H. Duerden
Director
Age: 68
Bio & Compensation - Reuters